Advanced aggressive fibromatosis: Effective palliation with chemotherapy

References

• Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol 1997;6:98–101.
   PubMedGoogle Scholar
• Bauernhofer T, Stöger H, Schmid M, Smola M, Gürtl-Lackner B, Höfler G, . Sequential treatment of recurrent mesenteric desmoid tumor. Cancer 1996;77:1061–5.
   PubMed Web of Science ®Google Scholar
• Tejpar S, Nollet F, Li C, . Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18: 6615–20.
   PubMed Web of Science ®Google Scholar
• Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997;151:329–34.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, . Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: A series of patients surgically treated at a single institution. J Clin Oncol 2003;21:1390–7.
   PubMed Web of Science ®Google Scholar
• Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, . Optimizing treatment of desmoids tumors. J Clin Oncol 2007;25:1785–91.
   PubMed Web of Science ®Google Scholar
• Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999;17:158–67.
   PubMed Web of Science ®Google Scholar
• Nuyttens JJ, Rust PF, Thomas CR, Turrisi AT, 3rd. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoids tumors. A comparative review of 22 articles. Cancer 2000;88:1517–23.
   PubMed Web of Science ®Google Scholar
• Sherman NE, Romsdahl M, Evans H, Zagars G, Oswald MJ. Desmoid tumors: A 20-year radiotherapy experience. Int J Radiat Oncol Biol Phys 1990;19:37–40.
   PubMed Web of Science ®Google Scholar
• Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: A systematic review. Ann Oncol 2003;14:181–90.
   PubMed Web of Science ®Google Scholar
• Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: Defying the dogma in oncology. J Clin Oncol 2006;24:11–2.
   PubMed Web of Science ®Google Scholar
• Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612–20.
   PubMed Web of Science ®Google Scholar
• Dufresne A, Penel N, Salas S, . Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrent aggressive fibromatosis (desmoids tumor): A FNCLCC/French Sarcoma Group phase II trial [abstract 10518]. J Clin Oncol 2009;27:15s.
   Google Scholar
• Gega M, Yanagi H, Yoshikawa R, Noda M, Ikeuchi H, Tsukamoto K, . Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoids tumors in association with familial adenomatous polyposis. J Clin Oncol 2006;24:102–5.
   PubMed Web of Science ®Google Scholar
• Hartley JA. Alkylating agents. Souhami R, Tannock I, Hohenberger P, . Oxford Textbook of Oncology. 2nd. New York, NY: Oxford University Press Inc; 2002.
   Google Scholar
• Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, . Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: Protection at the progenitor cell level. J Clin Oncol 1992; 10:1266–77.
   PubMed Web of Science ®Google Scholar
• Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoids tumors. Cancer 1989;64:1192–4.
   PubMed Web of Science ®Google Scholar
• Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pennacchioli E, . Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001;92:1259–64.
   PubMed Web of Science ®Google Scholar
• Skapek SX, Hawk BJ, Hoffer FA, Dahl GV, Granowetter L, Gebhardt MC, . Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol 1998;16:3021–7.
   PubMed Web of Science ®Google Scholar
• Pilz T, Pilgrim TB, Bisogno G, Knietig R, Koscielniak E, Carli M, . Chemotherapy in fibromatoses of childhood and adolescence: Results from the Cooperative soft tissue sarcoma study (CWS) and the Italian Cooperative study group (ICG-AIEOP). Klin Padiatr 1999;211:291–5.
   PubMedGoogle Scholar
• Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. Cancer 2003;97:134–5.
   PubMedGoogle Scholar
• Wehl G, Rossler J, Otten JE, Boehm N, Uhl M, Kontny U, . Response of progressive fibromatosis to therapy with liposomal doxorubicin. Onkologie 2004;27:526–52.
   Google Scholar
• Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer 2009;45:2930–4.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, . New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
   PubMed Web of Science ®Google Scholar